Commentary|Videos|November 18, 2026

Sending the Call for Fixed-Duration Bispecific Trials in Myeloma

Fact checked by: Ashley Gallagher, MA

Prerna Mewawalla, MD, discusses fixed-duration bispecifics to limit infection risk and real-world data showing poor outcomes after BCMA exposure.

Fixed-duration bispecific antibody therapy deserves rigorous study in multiple myeloma, according to Prerna Mewawalla, MD, director of the Stem Cell Transplant Program at Allegheny Health Network and associate professor at Drexel University College of Medicine, in an interview on treatment duration and outcomes after exposure to B-cell maturation antigen (BCMA) therapy. Her reasoning starts with speed.

Bispecifics produce very deep responses very quickly, she said, which raises the question of whether treatment must continue indefinitely. Infection risk remains a concern because the agents cause hypogammaglobulinemia. That risk declines over time and with measures such as intravenous immunoglobulin—still, the risk also persists. “Do you really need indefinite treatment for these patients,” Mewawalla asked.

Early evidence is encouraging but limited. She pointed to retrospective tedclistamab data and to cevostamab data in which fixed-duration therapy left patients in remission, although both involved small populations. “I think going forward, this is a reason why we need trials which actually work with fixed-duration bispecifics and not just indefinite use of bispecifics,” she said.

The need for better post-BCMA options is more clearly quantified. Mewawalla said real-world data from the US Myeloma Innovations Research Collaborative sharpen a familiar problem. “I think they put hard numbers on a problem we all feel clinically,” she said. “Once patients fail BCMA-directed therapy, out tools really get much weaker.”

Most BCMA-exposed patients had multiple prior lines, yet BCMA chimeric antigen receptor T-cell therapy clearly outperformed T-cell engagers, with response rates of approximately 79% vs 59% and median overall survival of 30 vs 12 months. Teclistamab in BCMA-exposed patients produced lower response rates and shorter progression-free survival than in BCMA-naïve patients (2.5 vs 10.0 months), with especially poor outcomes within 6 months of a prior BCMA agent.

How long the gap between BCMA-directed agents should be is a frequent topic of discussion, Mewawalla said. Honestly, no one knows the answer, she added. In clinical practice, clinicians generally go with a 6-month gap.


Related to this article